Evidence map›Paper›PMID 34624096›Full record

ArticleBlood2022

ETV6-NCOA2 fusion induces T/myeloid mixed-phenotype leukemia through transformation of nonthymic hematopoietic progenitor cells.

Hila Fishman, Shreyas Madiwale, Ifat Geron, Vase Bari, Wouter Van Loocke, Yael Kirschenbaum, Itamar Ganmore, Eitan Kugler, Avigail Rein-Gil, Gilgi Friedlander and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Exploring the molecular mechanism of Xiao Ji (Asian biomedicine : research, reviews and news · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 5 countries.

Hila FishmanSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Shreyas MadiwaleSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Ifat GeronSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Vase BariCancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH.ORCID 0000-0003-4392-3430
Wouter Van LoockeDepartment of Pediatrics and Genetics, Ghent University, Ghent, Belgium.ORCID 0000-0002-7385-0546
Yael KirschenbaumSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Itamar GanmoreSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Eitan KuglerSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Avigail Rein-GilSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-9399-2656
Gilgi FriedlanderThe Mantoux Bioinformatics Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel.
Ginette SchibyInstitute for Pathology Laboratory, Hematology Institute, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel.
Yehudit BirgerSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sabine StrehlChildren's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.ORCID 0000-0002-0179-0628
Jean SoulierGenomes and Cell Biology of Disease, Hôpital Saint-Louis, Paris, France.
Birgit KnoechelDana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.ORCID 0000-0002-8040-0535
Adolfo FerrandoInstitute for Cancer Genetics, Columbia University, New York, NY.
Sharon Noy-LotanRina Zaizov Pediatric Hematology Oncology Division, Schneider Children's Medical Center of Israel, Petah Tikvah, Israel.
Arnon NaglerSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
James C MulloyCancer and Blood Diseases Institute, Cincinnati Children's Hospital, Cincinnati, OH.
Pieter Van VlierbergheDepartment of Pediatrics and Genetics, Ghent University, Ghent, Belgium.
Shai IzraeliSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.ORCID 0000-0002-6938-2540
Tel Aviv University · ILCincinnati Children's Hospital Medical Center · USGhent University Hospital · BEBoston Children's Hospital · USCancer Genetics (United States) · USHôpital Saint-Louis · FRSchneider Children's Medical Center · ILSheba Medical Center · ILSt Anna Children's Hospital · ATWeizmann Institute of Science · IL

Funding

Molecular pathways and targeted therapies in human leukemiaR35CA210065 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FERRANDO, ADOLFO A. · 2017 to 2021
$4.7M
Epigenetic mechanisms of drug resistance in T-cell acute lymphoblastic leukemiaK08CA191091 · NCI · DANA-FARBER CANCER INST · PI KNOECHEL, BIRGIT · 2015 to 2019
$886k
NCI NIH HHS K08 CA191091NCI NIH HHS R35 CA210065
6 · The paper itself

Abstract

Mixed-phenotype acute leukemia is a rare subtype of leukemia in which both myeloid and lymphoid markers are co-expressed on the same malignant cells. The pathogenesis is largely unknown, and the treatment is challenging. We previously reported the specific association of the recurrent t(8;12)(q13;p13) chromosomal translocation that creates the ETV6-NCOA2 fusion with T/myeloid leukemias. Here we report that ETV6-NCOA2 initiates T/myeloid leukemia in preclinical models; ectopic expression of ETV6-NCOA2 in mouse bone marrow hematopoietic progenitors induced T/myeloid lymphoma accompanied by spontaneous Notch1-activating mutations. Similarly, cotransduction of human cord blood CD34+ progenitors with ETV6-NCOA2 and a nontransforming NOTCH1 mutant induced T/myeloid leukemia in immunodeficient mice; the immunophenotype and gene expression pattern were similar to those of patient-derived ETV6-NCOA2 leukemias. Mechanistically, we show that ETV6-NCOA2 forms a transcriptional complex with ETV6 and the histone acetyltransferase p300, leading to derepression of ETV6 target genes. The expression of ETV6-NCOA2 in human and mouse nonthymic hematopoietic progenitor cells induces transcriptional dysregulation, which activates a lymphoid program while failing to repress the expression of myeloid genes such as CSF1 and MEF2C. The ETV6-NCOA2 induced arrest at an early immature T-cell developmental stage. The additional acquisition of activating NOTCH1 mutations transforms the early immature ETV6-NCOA2 cells into T/myeloid leukemias. Here, we describe the first preclinical model to depict the initiation of T/myeloid leukemia by a specific somatic genetic aberration.

Indexed as

Gene Expression Regulation, LeukemicAnimalsCells, CulturedCell Transformation, NeoplasticETS Translocation Variant 6 ProteinFemaleHematopoietic Stem CellsHumansLeukemia, MyeloidMiceMice, Inbred C57BLMice, SCIDNuclear Receptor Coactivator 2Oncogene Proteins, FusionProto-Oncogene Proteins c-etsRepressor ProteinsETS Translocation Variant 6 ProteinNCOA2 protein, humanNuclear Receptor Coactivator 2Oncogene Proteins, FusionProto-Oncogene Proteins c-etsRepressor Proteins

Identifiers

PMID34624096
PMCPMC9906988
OpenAlexW3204925275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.